Brain-Computer Interface Company Synchron Snags $200M

Brain-Computer Interface Company Synchron Raises $200M

Synchron, a New York-based developer of non-surgical brain-computer interface technology, announced a $200 million Series D funding round. This financing aims to accelerate the commercialization of its first-generation Stentrode brain-computer interface (BCI) and support the development of a next-generation device.

Funding Details and Investors

The recent investment brings Synchron’s total funding to $345 million. Double Point Ventures led this round, joined by existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New participants include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.

About the Stentrode BCI Platform

Synchron's Stentrode system is the first brain-computer interface implanted via an endovascular method. It translates brain signals into digital commands without requiring open-brain surgery. The device is inserted through a minimally invasive catheter procedure and connects wirelessly to record neural activity from the motor cortex.

“Our Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices.”

Significance of the Technology

Author’s summary: Synchron’s $200M funding will fast-track commercialization of its pioneering endovascular brain-computer interface and drive innovation in next-generation neurotechnology.

more

Medical Device and Diagnostic industry Medical Device and Diagnostic industry — 2025-11-07

More News